Robert F Kelley

List of Publications by Year
in descending order

36 papers	2,829 citations	279798 23 h-index	361022 35 g-index
36 all docs	36 docs citations	36 times ranked	3027 citing authors

#	Article	IF	Citations
1	Triggering Cell Death. Molecular Cell, 1999, 4, 563-571.	9.7	412
2	A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL. Biochemistry, 2000, 39, 633-640.	2.5	262
3	Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling. Journal of Biological Chemistry, 2005, 280, 2205-2212.	3.4	237
4	A strategy for risk mitigation of antibodies with fast clearance. MAbs, 2012, 4, 753-760.	5.2	200
5	In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18601-18606.	7.1	190
6	Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab. Journal of Molecular Biology, 2013, 425, 1330-1339.	4.2	133
7	Glycan Shifting on Hepatitis C Virus (HCV) E2 Glycoprotein Is a Mechanism for Escape from Broadly Neutralizing Antibodies. Journal of Molecular Biology, 2013, 425, 1899-1914.	4.2	105
8	Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs, 2014, 6, 1255-1264.	5.2	104
9	Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. Biochemistry, 1992, 31, 5434-5441.	2.5	103
10	Analysis of the Factor VIIa Binding Site on Human Tissue Factor: Effects of Tissue Factor Mutations on the Kinetics and Thermodynamics of Binding. Biochemistry, 1995, 34, 10383-10392.	2.5	102
11	Effects of altered FcÎ³R binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs, 2013, 5, 896-903.	5.2	90
12	Antibody variable region binding by Staphylococcal protein A: Thermodynamic analysis and location of the Fv binding site on Eâ€domain. Protein Science, 1999, 8, 1423-1431.	7.6	86
13	Inhibiting Alternative Pathway Complement Activation by Targeting the Factor D Exosite. Journal of Biological Chemistry, 2012, 287, 12886-12892.	3.4	75
14	Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5679-5684.	7.1	73
15	The Tissue Factor Region That Interacts with Substrates Factor IX and Factor X. Biochemistry, 2000, 39, 7380-7387.	2.5	68
16	A Soluble Tissue Factor Mutant Is a Selective Anticoagulant and Antithrombotic Agent. Blood, 1997, 89, 3219-3227.	1.4	67
17	Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs, 2013, 5, 872-881.	5.2	67
18	Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. Journal of Biological Chemistry, 2015, 290, 29732-29741.	3.4	67

#	Article	IF	Citations
19	Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab. Molecular Pharmaceutics, 2016, 13, 2996-3003.	4.6	62
20	The Tissue Factor Region That Interacts with Factor Xa in the Activation of Factor VII. Biochemistry, 2001, 40, 675-682.	2.5	49
21	Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules. Translational Vision Science and Technology, 2019, 8, 1.	2.2	38
22	The 1.85 Ã... resolution crystal structures of tissue factor in complex with humanized fab d3h44 and of free humanized fab d3h44: revisiting the solvation of antigen combining sites 1 1Edited by I. Wilson. Journal of Molecular Biology, 2001, 313, 83-97.	4.2	36
23	Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. MAbs, 2017, 9, 756-766.	5.2	33
24	In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation. MAbs, 2014, 6, 437-445.	5.2	23
25	Potent Bifunctional Anticoagulants:Â Kunitz Domainâ"Tissue Factor Fusion Proteins. Biochemistry, 1997, 36, 5607-5611.	2.5	20
26	Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye. PLoS ONE, 2019, 14, e0218613.	2.5	20
27	Hinge bending within the cytokine receptor superfamily revealed by the 2.4 Ã... crystal structure of the extracellular domain of rabbit tissue factor. Protein Science, 1998, 7, 1106-1115.	7.6	19
28	Thermodynamics of ligand binding and denaturation for his64 mutants of tissue plasminogen activator kringle-2 domain. Proteins: Structure, Function and Bioinformatics, 1991, 11, 35-44.	2.6	17
29	Similar Molecular Interactions of Factor VII and Factor VIIa with the Tissue Factor Region that Allosterically Regulates Enzyme Activity. Biochemistry, 2004, 43, 1223-1229.	2.5	17
30	Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye. MAbs, 2017, 9, 1297-1305.	5.2	16
31	Methods to Engineer and Identify IgG1 Variants with Improved FcRn Binding or Effector Function. Methods in Molecular Biology, 2012, 901, 277-293.	0.9	12
32	A Novel Soluble Tissue Factor Variant with an Altered Factor VIIa Binding Interface. Journal of Biological Chemistry, 1998, 273, 4149-4154.	3.4	8
33	Protein conjugates and fusion proteins as ocular therapeutics. Drug Discovery Today, 2019, 24, 1440-1445.	6.4	8
34	In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Molecular Pharmaceutics, 2019, 16, 86-95.	4.6	6
35	Molecular Assessment of Monoclonal Antibody-Based Therapeutics Enabling Lead Selection for Clinical Development. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 153-180.	0.6	4
36	Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology. Molecular Pharmaceutics, 2022, , .	4.6	0